Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer

Clinical Oncology

Volumn 12, Issue 4, 2000, Pages 251-255

  Iaffaioli, R V ^a,h   Tortoriello, A ^b   Santangelo, M ^c   Turitto, G ^b   Libutti, M ^d   Benassai, G ^e   Frattolillo, A ^b   Ciccarelli, P D ^f   De Rosa, P ^f   Crovella, F ^g   Carbone, I ^g   Barbarisi, A ^e  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Medicina Oncologica Clinica Villalba   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d ASL Napoli 1   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Clinica Generale e Trapianti d'Organo Ateneo Federico II Napoli   (Italy)

^g Chirurgia Generale Ospedale Oliveto Citra   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Breast cancer; Gemcitabine; Ovarian cancer; Paclitaxel

Indexed keywords

CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIVER ENZYME; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; ENZYME DEFECT; FEMALE; HEART ARRHYTHMIA; HUMAN; KIDNEY DISEASE; MAXIMUM PERMISSIBLE DOSE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0033832392     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2000.9167     Document Type: Article

References (12)

1. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31.
2. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a Phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-6.
3. Blackstein M, Vogel CL, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer [abstract]. Proc ASCO 1996;15:13.
4. Lund B, Neijt JP. Gemcitaine in cisplatin-resistant ovarian cancer. Semin Oncol 1996;23:(Suppl 10):72-6.
5. Nogue M, Cirera L, Arcusa M, et al. Activity of gemcitabine and cisplatin in advanced epithelial ovarian cancer: preliminary Phase II results [abstract]. Proc ASCO 1997;16:1335.
6. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1993;332:1004-14.
7. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
8. Miller AB, Hoogstraten B, Staguet M, et al. Reporting results of cancer research. Cancer 1981;47:207-14.
9. Androulakis N, Kouroussis C, Kakolyris S, et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicentric Phase II study. Ann Oncol 1998;9:1127-30.
10. Broxmeyer HE, Benninger L, Patel SR, et al. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol 1994;22:100-2.
11. Vogel CL. Current status of salvage chemotherapy for refractory advanced breast cancer. Oncology 1996;10(Suppl 6):7-15.
12. Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter Phase II trial. Ann Oncol 1999;10:211-5.